News >

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

Published: Wednesday, Mar 28, 2018

Denise Uyar, MD

Denise Uyar, MD
First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab (Keytruda), followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Of the six patients with no evidence of disease, the time from surgery ranged from 3 to 13 months. The 3 patients with progressive disease were 6, 8, and 14 months from surgery.
Uyar D, Bishop EA, Bradley WH, et al. Preliminary data on the use of combination carboplatin, paclitaxel and pembrolizumab therapy for ovarian cancer. Presented at: 2018 SGO Annual Meeting; March 24-27, 2018; New Orleans, LA. Abstract 100.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication